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Abstract: Osteosarcoma is the most common form of primary bone cancer. Over 20% of osteosarcoma
patients present with pulmonary metastases at diagnosis, and nearly 70% of these patients fail
to respond to treatment. Previous work revealed that human and canine osteosarcoma cell lines
are extremely sensitive to the therapeutic proteasome inhibitor bortezomib in vitro. However,
bortezomib has proven disappointingly ineffective against solid tumors including sarcomas in
animal experiments and clinical trials. Poor tumor penetration has been speculated to account for
the inconsistency between in vitro and in vivo responses of solid tumors to bortezomib. Here we
show that the second-generation proteasome inhibitor ixazomib, which reportedly has enhanced
solid tumor penetration compared to bortezomib, is toxic to human and canine osteosarcoma cells
in vitro. We used experimental osteosarcoma metastasis models to compare the efficacies of ixazomib
and bortezomib against primary tumors and metastases derived from luciferase-expressing KRIB
or 143B human osteosarcoma cell lines in athymic mice. Neither proteasome inhibitor reduced
the growth of primary intramuscular KRIB tumors, however both drugs inhibited the growth of
established pulmonary metastases created via intravenous inoculation with KRIB cells, which were
significantly better vascularized than the primary tumors. Only ixazomib slowed metastases from
KRIB primary tumors and inhibited the growth of 143B pulmonary and abdominal metastases,
significantly enhancing the survival of mice intravenously injected with 143B cells. Taken together,
these results suggest ixazomib exerts better single agent activity against osteosarcoma metastases
than bortezomib. These data provide hope that incorporation of ixazomib, or other proteasome
inhibitors that penetrate efficiently into solid tumors, into current regimens may improve outcomes
for patients diagnosed with metastatic osteosarcoma.
Keywords: osteosarcoma; proteasome inhibitors; bortezomib; ixazomib
1. Introduction
Osteosarcoma is the most common form of primary bone cancer and its incidence peaks in
adolescence [1]. Osteosarcomas typically arise due to p53 and RB1 mutations in osteoblasts or
their precursors in the long bones such as the tibia, femur or proximal humerus [2]. Neoadjuvant
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administration of chemotherapies including doxorubicin, cisplatin and methotrexate alongside surgery
to remove the tumor or affected limb has improved the five-year survival rate for patients diagnosed
with osteosarcoma from approximately 20% in the 1960s to 60% in the 1980s [3,4]. Between 20%
and 30% of patients diagnosed with osteosarcoma present with pulmonary metastases, and for these
patients the five-year survival rate diminishes to only 20% to 30% [5]. Given the lack of improvement
in patient outcomes since the 1980s, particularly for those with pulmonary metastases, new therapies
are required for osteosarcoma.
The proteasome is one of many molecular targets identified for the development of novel anti-cancer
therapies. The first-generation therapeutic proteasome inhibitor, bortezomib, is FDA-approved for
the treatment of multiple myeloma and mantle cell lymphoma [6,7]. Bortezomib induces cell death
through proteotoxic stress and altering the equilibrium of pro/anti-apoptotic proteins by inhibiting the
degradation of ubiquitinated proteins by the 20S proteasome [8]. Multiple studies have documented
the sensitivity of osteosarcoma cells to bortezomib in vitro and in vivo [9–11]. Despite promising
preclinical data, a phase 1 clinical trial investigating the efficacy of bortezomib in pediatric patients
with solid tumors (including two osteosarcoma patients) [12] and a phase II clinical trial investigating
the efficacy of bortezomib for treatment of metastatic sarcomas (including a single osteosarcoma
participant) [13] concluded that the drug had minimal activity in these contexts as a single agent.
Additional studies have shown that bortezomib has poor anti-cancer activity against a range of solid
tumors in vivo [14,15]. A review of 32 clinical trials that tested the efficacy of bortezomib against solid
carcinomas found no evidence of a therapeutic effect when used as a single agent or when combined
with chemotherapies [16].
Numerous hypotheses have been postulated to explain the poor responses of solid tumors to
proteasome inhibitors [8,17]. For example, TP53 mutations, which are common in solid cancers but rare
in multiple myeloma and other hematological cancers [18], decreased sensitivity to bortezomib [19,20].
KRAS mutations, which occur in the majority of pancreatic cancers [21], were also linked to resistance
to proteasome inhibition [22]. Discrepancies between the promising in vitro potency of bortezomib
towards cells derived from some solid cancer types, versus its minimal efficacy in patients with those
solid tumors may be explained by its inability to penetrate tumors. Bortezomib only effectively reduced
the growth of well vascularized tumors [23–27]. Researchers have explored strategies to improve
the bioavailability of bortezomib: packaging the drug into liposomes that permeate preferentially
through tumor vasculature was far more effective at treating xenograft solid tumors than unpackaged
bortezomib [28].
Second-generation proteasome inhibitors have subsequently been developed including carfilzomib
and ixazomib, both of which are FDA-approved to treat relapsed multiple myeloma [29,30]. Ixazomib
is the first orally available proteasome inhibitor that exhibited markedly improved activity against
solid tumors, relative to bortezomib [15]. In pre-clinical models, ixazomib reduced the growth of solid
tumors and enhanced survival compared to bortezomib [15]. Osteosarcoma cells were found to be
sensitive to ixazomib in vitro [9,31], but no studies have investigated the anti-osteosarcoma efficacy of
ixazomib in vivo.
One of the challenges in overcoming the stagnant response rates of osteosarcoma patients is that
the extremely low incidence of the disease [32] makes it difficult to establish clinical trials to evaluate
new therapies. Several of the clinical trials that have occurred in more recent years failed to identify
any new treatments that would improve patient outcome over the currently used therapies [13,33–35].
Dogs with spontaneous osteosarcoma are a valuable translational model to evaluate new therapies
from pre-clinical in vitro and rodent models and improve the likelihood of new treatments being
successfully implemented into human patients with osteosarcoma. [36,37]. Dogs and humans with
osteosarcoma share similar genetics, tumor-immune interactions, cellular environment, tumor cell
morphology, prognostic factors and natural disease course (with a high rate of pulmonary metastasis)
and undergo similar treatments including surgery and chemotherapy. A key difference between the
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two is that the incidence of osteosarcoma in dogs is 27 times higher than humans, facilitating clinical
trials [38].
Here we compared the effectiveness of bortezomib and ixazomib in vivo, in mice implanted with
intramuscular osteosarcomas or bearing pulmonary and abdominal metastases. Neither proteasome
inhibitor was active against the primary tumors, but ixazomib reduced the formation and slowed the
progression of pulmonary and abdominal metastases, as well as enhancing survival. Both proteasome
inhibitors were more effective against lung tumors that were relatively well vascularized compared to
less vascularized intramuscular tumors.
2. Results
2.1. Established Human Osteosarcoma Cell Lines and Freshly Resected Canine Osteosarcoma Cells Are
Sensitive to Proteasome Inhibitors at Physiologically Relevant Concentrations
We previously reported the in vitro sensitivity of canine and human osteosarcoma cells to a panel
of proteasome inhibitors including bortezomib and ixazomib [9]. In this study we compared the
efficacy of bortezomib to ixazomib in vivo, using human osteosarcoma cell lines that are tumorigenic
and metastasize to the lungs of athymic mice [39–41]. We first assayed the in vitro sensitivity of these
cell lines, and cells isolated from resected canine osteosarcomas.
Cells were treated at concentrations between 0.1% and 10x the peak plasma concentration (Cmax)
of bortezomib (Cmax = 580 nM [42]), ixazomib (Cmax = 300 nM [43]), carfilzomib (Cmax = 3.5 µM [44]),
doxorubicin (Cmax = 1.7 µM [45]) or cisplatin (Cmax = 5.5 µM [46]) for 24 (Figure 1A) or 48 h (Figure 1B).
After 24 h, the proteasome inhibitors reduced cell viability below 20% in all three cell lines at
concentrations below Cmax. In contrast, doxorubicin and cisplatin failed to reduce cell viability below
50% at concentrations equal to or below Cmax. After 48 h, the proteasome inhibitors greatly reduced
cell viability at concentrations between 1% and 10% Cmax whereas doxorubicin and cisplatin only
reduced cell viability below 20% at 100% Cmax. Of the three proteasome inhibitors used, bortezomib
was the only drug that exerted a robust effect in all cell lines when applied at 1% Cmax. Ixazomib was
the least effective, even considering that the molar concentrations of ixazomib used were around half
those of bortezomib. This probably reflects the six-fold faster dissociation of ixazomib than bortezomib
from the proteasome [15].
While the sensitivity of osteosarcoma cell lines to proteasome inhibitors was promising, we wanted
to confirm whether this could be an artifact of in vitro culturing. Canine and human osteosarcomas
are extremely similar and share the same treatments of doxorubicin and platinating agents [36,47,48],
but osteosarcoma is more common in dogs than people [38], and canine tumors are typically resected
without administration of neo-adjuvant chemotherapy that human patients usually receive [49].
These factors led us to assess the ex vivo sensitivity of canine osteosarcoma cells to proteasome
inhibitors and chemotherapy drugs. We assayed the sensitivity of cells from six canine osteosarcomas
to 48 h exposures to bortezomib, ixazomib, carfilzomib, doxorubicin and carboplatin, the platinating
agent typically used to treat dogs: [50] (Cmax = 224 µM [51]) (Figure 1C). We also combined the
proteasome inhibitors with the chemotherapies to determine cooperation between the drugs. Like the
established human osteosarcoma cell lines, all six canine samples were sensitive to the proteasome
inhibitors, however the chemotherapies were far less effective with the best responses reducing viability
by half at Cmax. When the proteasome inhibitors were combined with doxorubicin or carboplatin,
the treatments were barely additive. This may be a consequence of doxorubicin’s cytotoxicity being
dependent on cell division [52] while proteasome inhibitors halt the cell cycle [9,10].
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Figure 1. Established and minimally passaged primary osteosarcoma cell lines are more sensitive to 
proteasome inhibitors than current treatments for osteosarcoma. Established human osteosarcoma 
cell lines were treated with therapeutic proteasome inhibitors; bortezomib, carfilzomib and ixazomib 
or current treatments at 0.1%, 1%, 10%, 100% or 10x each drug’s Cmax for 24 h (A) or 48 h (B). Cells 
from six resected canine osteosarcoma tumors were treated with proteasome inhibitors, current 
treatments for canine osteosarcoma or a combination of each drug class at 1%, 10% or 100% Cmax for 
48 h (C). All viabilities reported are relative to untreated samples (n = 3 +/− SEM). 
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proteasome inhibitors than current treatments for osteosarcoma. Established hu an osteosarcoma cell
lines were treated with therapeutic proteasome inhibitors; bortezomib, carfilzomib and ixazomib or
current treatments at 0.1%, 1%, 10%, 100% or 10x each drug’s Cmax for 24 h (A) or 48 h (B). Cells from
six resected canine osteosarcoma tumors were treated with proteasome inhibitors, current treatments
for canine osteosarcoma or a combination of each drug class at 1%, 10% or 100% Cmax for 48 h (C).
All viabilities reported are relative to untreated samples (n = 3 +/− SEM).
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2.2. Ixazomib and Bortezomib Inhibit the Formation and Growth of Pulmonary KRIB Osteosarcoma Metastases
But Not Primary Intramuscular Tumors
While the tolerability of 1 mg/kg bortezomib twice weekly is well established [10,15,53],
the maximum tolerated dose of ixazomib is less defined in immunocompromised mice: in one
study, 5 mg/kg [54] was intolerable, but in another 11 mg/kg biweekly resulted in no weight loss [55].
We found that athymic BALB/c nude mice tolerated 5 mg/kg ixazomib twice weekly for four weeks,
but not 7 mg/kg (Supplementary Figure S1).
We compared the efficacy of ixazomib and bortezomib in mice bearing intramuscular KRIB-luc
tumors, which reliably form lung metastases in two to three weeks [39] to determine if either drug could
reduce the growth of primary tumors or inhibit the formation of metastases. The mean bioluminescence
readings of the primary tumors in mice treated with saline, bortezomib or ixazomib were similar in the
first 21 days of the experiment (Figure 2A) after which the bioluminescent values became unreliable,
presumably due to poor uptake of luciferin in larger tumors. By 10 days after cell inoculation, mice
began to develop lung metastases, which could be detected by in vivo bioluminescence imaging.
The mean growth of lung tumors was lower on average in mice treated with ixazomib or bortezomib
than vehicle during the four weeks of treatment, however these differences were not statistically
significant (Figure 2B). Promisingly, ixazomib significantly delayed the formation of detectable lung
metastases compared to the saline treated mice (Figure 2C), consistent with it having improved
pharmacokinetics relative to bortezomib [15]. Primary tumor weights at the endpoint of the experiment
were no different between the three treatments (Figure 2D), which was surprising given that ixazomib
has been demonstrated to have enhanced solid tumor penetration compared to bortezomib [15].
On average the overall tumor burden in the lungs of ixazomib-treated mice was lower than those that
received saline or bortezomib (Figure 2E), however this difference was not significant.
The presence of treatment-resistant primary tumors, which could continuously seed cells via the
circulation to the lungs, may have confounded evaluation of the efficacy of the proteasome inhibitors
against lung metastases. To address this, we explored the anti-metastatic efficacy of ixazomib compared
to bortezomib or saline further in mice bearing “experimental” lung metastases in the absence of
primary tumors. This was achieved by intravenous injection of KRIB-luc cells, which we previously
determined could form lung metastases [41]. Mice were imaged twice weekly and allocated alternately
to a treatment group the day after bioluminescence was detected in their lungs. Two ixazomib treated
mice and one bortezomib treated mouse that had undetectable or small metastases with stable growth
two weeks after their final treatment were kept alive until 70 days post tumor cell detection. All other
mice were culled two weeks after their final treatment. Both ixazomib and bortezomib slowed the
growth of established lung metastases compared to mice receiving saline (Figure 3A,B). Ixazomib
also enhanced the survival of mice (Figure 3C) and resulted in a lower tumor burden in the lungs
when measured ex vivo (Figure 3D) at the endpoint of the experiment (despite surviving longer
than saline- or bortezomib-treated mice). While all saline-treated mice and two bortezomib-treated
mice required euthanasia due to intolerable tumor-related symptoms that developed after the final
treatments, all ixazomib treated mice remained asymptomatic throughout the experiment (Figure 3C).
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Other studies have reported a relationship between the effectiveness of bortezomib against solid
tumors and their vascularization [27]. We assayed for LLVYase activity, which reflects chymotrypsin-like
activity of the proteasome [56] in tumors from treated and untreated mice. We chose to assay the
chymotrypsin-like protease activity because bortezomib and ixazomib inhibit this proteolytic activity
with similar low nanomolar potencies, and both drugs inhibit it around 10-fold more efficiently
than proteasomal caspase-like activity and around 1000-fold more efficiently than the trypsin-like
activity [15]. We therefore estimate that this assay detects around 90% of the total proteolytic activity
of the proteasome, and because the drugs have very similar specificities, the assay probably provides a
fair comparison of their inhibitory actions in these tissues. Both proteasome inhibitors significantly
inhibited LLVYase activity in lung tumor tissue compared to saline, whereas neither drug inhibited
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LLVYase activity in intramuscular tumor tissue compared to saline (Figure 4A). Vascularity in primary
intramuscular tumors and lung metastases was quantified by immunofluorescence, which revealed
an increased density of CD31 positive blood vessels in CD44 positive lung metastases compared to
primary tumors (Figure 4B–D).
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2.3. Ixazomib Inhibits the Growth of 143B Osteosarcoma Metastases and Enhances Survival Compared to Saline
Treated Mice
Osteosarcoma has also been reported to metastasize to organs other than the lungs in some
cases [57,58]. We have previously described an aggressive osteosarcoma model where luciferase-tagged
143B cells injected intravenously into nude mice formed lung, kidney and liver metastases in less
than two weeks [41]. Unlike the KRIB metastatic model, only ixazomib reduced the growth of
143B lung tumors whereas bortezomib was ineffective (Figure 5A). Ixazomib, not bortezomib, also
delayed the formation of abdominal metastases (liver and/or kidneys) compared to saline (Figure 5B).
Ixazomib-treated mice survived longer and some were asymptomatic at the endpoint of the experiment,
whereas most saline- and bortezomib-treated mice required euthanasia due to intolerable tumor-related
symptoms (Figure 5C–E). The most striking difference between ixazomib, compared to saline and
bortezomib, was the reduced overall tumor burden in the lungs, liver and kidneys ex vivo (Figure 5E).
The ex vivo bioluminescence of the lungs in ixazomib-treated mice was at least 100-fold lower than the
mice treated with saline or bortezomib, despite being culled up to 21 days later.
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vivo to compare overall tumor burden in each mouse between treatment groups (E). Rates of growth of
tumors and survival between treatment groups were compared (F). (n = 6 for saline and 7 for ixazomib
and bortezomib, +/− SEM).
Cancers 2020, 12, 1207 10 of 18
2.4. Resected KRIB-luc and 143B-luc Osteosarcoma Cells Do Not Acquire Resistance During In Vivo Treatment
with Proteasome Inhibitors
To determine if osteosarcoma cells acquired resistance during in vivo treatment with either
bortezomib or ixazomib, we resected and disaggregated 143B-luc and KRIB-luc lung metastases for ex
vivo sensitivity analysis. In vivo exposure to proteasome inhibitors (or saline) did not affect the in vitro
sensitivity of 143B-luc cells (Figure 6A,B) or KRIB-luc cells (Figure 6C,D) to bortezomib or ixazomib.
The similar sensitives of the ex vivo treated cells compared to naïve parental cells to the proteasome
inhibitors suggests that any poor efficacy observed in vivo may relate to the local concentration of the
drug experienced by the osteosarcoma cells in vivo.
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3. Discussion
The stagnant progression in the outcome of patients diagnosed with pulmonary osteosarcoma
metastases since the 1980s [4] underpins the urgent need for therapies to be developed or repurposed to
treat metastatic osteosarcoma. Several studies have reported the toxicity of bortezomib to osteosarcoma
cells [9–11,59], however none of the osteosarcoma patients who have received bortezomib in clinical
trials exhibited objective responses [12,13]. The second-generation proteasome inhibitor ixazomib,
which was shown to possess enhanced solid tumor penetration compared to bortezomib [15], was
reported to also be toxic to osteosarcoma cells in vitro [9,31] but its potential had not been evaluated
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in vivo. In this study, we compared the efficacy of ixazomib to bortezomib in pre-clinical models of
primary and metastatic osteosarcoma in nude mice. While both drugs inhibited the growth of KRIB-luc
lung tumors, only ixazomib reduced the growth and formation of 143B-luc metastases and prolonged
survival in both metastatic models.
The in vitro response of established human cell lines and primary canine osteosarcoma cells
to proteasome inhibitors was extremely homogenous: all three proteasome inhibitors substantially
reduced cell viability at their respective Cmax. In contrast, the chemotherapies only appeared to
be effective at concentrations equal to or exceeding their peak concentration achievable in patients.
The substantial in vitro sensitivity to proteasome inhibitors implies that, unlike other solid cancer
types in which resistance to proteasome inhibition may reflect intrinsic resistance [8,17], osteosarcomas
would be expected to respond to proteasome inhibitors if intratumoral levels could be achieved that
resemble those in the blood.
Ixazomib was able to inhibit the growth of the pulmonary metastases in both models of metastatic
osteosarcoma used in this study, but all mice had detectable lung tumors when examined ex vivo at
the endpoint of the experiments. Unfortunately, the nude mice used in this study were more sensitive
to ixazomib-induced toxicities than previously reported [15]: they failed to tolerate administration
exceeding 5 mg/kg twice per week. It is possible that increasing the frequency in administration or
dose of ixazomib would elicit greater anti-tumor activity than we observed if intolerable symptoms
could be avoided, but it is not clear how the therapeutic window in different mouse strains would
compare to that in human (or canine) patients. Alternatively, the sub-curative efficacy of ixazomib
against metastatic osteosarcoma may augment responses to current osteosarcoma treatments. Several
pre-clinical studies and clinical trials have already highlighted cooperation or synergy when bortezomib
or ixazomib are combined with platinating agents [60–64] or doxorubicin [65,66] to treat solid tumors.
The cooperation between these drug classes may be a result of proteasome inhibitors improving the
uptake of platinating agents into cells [67] or enhancing the ability of chemotherapies like doxorubicin
to penetrate solid tumors by reducing the density of the extracellular matrix [65].
Given the reportedly enhanced solid tumor penetration of ixazomib over bortezomib [15], we were
disappointed that neither was effective against primary intramuscular tumors. Consistent with
this observation, lysates from primary tumors resected from treated and untreated mice harbored
similar proteasome activity. Those data reflect the average LLVYase activities one hour after drug
administration. Peripheral regions of treated tumors, or areas surrounding the very rare vessels,
may have experienced drug-mediated suppression of proteasome activity at this time, which was not
evident in assays of total lysates. A time course analysis may have revealed slower drug penetration
into areas more distant from vessels. In contrast, equivalent analysis of lung tumors, which were
better vascularized, did reveal a difference in average proteasome activity between tumors from
treated and untreated mice, which aligned with our observation that the drugs had greater impact
on the growth of metastases than primary tumors. Thus, vascularity may account for the differing
responses of intramuscular versus lung tumors to treatment. Similar results have also been published
in a study comparing the effectiveness of bortezomib against well- and poorly-vascularized solid
tumors [27]. Our work extends these findings and suggests that this is likely a feature of proteasome
inhibitors as a class. Intriguingly, we detected lower proteasome activity in untreated lung tumors than
untreated primary tumors, suggesting a biochemical adaptation to the different microenvironments
(lung versus muscle). Maybe the lower basal proteasome activity in lung tumors rendered those
cells more sensitive to the toxic effects of proteasome inhibition. Further work will be needed to
explore these possibilities. The limited efficacy of bortezomib and ixazomib against the primary
tumors could also be a consequence of the anti-angiogenic properties of proteasome inhibitors in
general [68], which could suppress the efficacy of chemotherapies or subsequent administrations of the
proteasome inhibitors. Tumor vascularity is also a critical factor in how osteosarcoma patients respond
to chemotherapy in the clinic. Patients with a higher micro-vessel density in their primary tumors
had an improved response to treatment compared to those with reduced micro-vessel density [69].
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While our work revealed that proteasome inhibitors were only effective against pulmonary metastases,
which were better vascularized than primary tumors, pulmonary osteosarcoma metastases in patients
are similarly better vascularized than primary tumors [70], providing hope that our data may translate
to a patient context. Vascular endothelial growth factor (VEGF) may be a useful biomarker to identify
osteosarcoma patients whose tumors may be most likely to respond proteasome inhibitors, given that
serum levels of VEGF in osteosarcoma patients correlate well with intra-tumoral levels [71].
One approach to improving the bioavailability of the proteasome inhibitors in primary
osteosarcomas may be to package them in liposomes that preferentially permeate through tumor
vasculature, which has already proven to be effective against other models of solid tumors [28].
Alternatively, complementing proteasome inhibitors with therapeutic agents that can remodel tumor
vasculature to improve drug uptake into tumor tissue may be a more viable approach. Recently
published work [72] revealed that thalidomide can improve the uptake of cisplatin in solid tumors by
promoting vascular maturity while simultaneously reducing the frequency of metastases by decreasing
tumor angiogenesis. It would be interesting to see if thalidomide is able to enhance the efficacy of
proteasome inhibitors as well.
As this study was conducted with nude mice, which possess an innate immune system but
lack T cells [73], the efficacy of both proteasome inhibitors may have been underestimated in our
experiments. Other studies have demonstrated in pre-clinical models of solid tumors that bortezomib
could sustain T-cell activation signals, synergistically enhancing survival of mice administered with
naïve CD8+T-cells and sensitizing tumor cells to T-cell mediated lysis [74,75]. Future work should also
investigate whether ixazomib has improved anti-osteosarcoma activity in immunocompetent mice.
4. Materials and Methods
4.1. Cell Lines
Parental human osteosarcoma cells KRIB, 143B and KHOS provided by Nicholas Saunders
and derivatives expressing luciferase and mCherry [39] were cultured in DMEM media (Invitrogen;
Waltham, MA, USA) supplemented with 10% FBS. Cell lines were authenticated by short tandem repeat
profiling. All cell lines were cultured in humidified incubators at 37 ◦C in 5% CO2. For ex vivo treatment
of human osteosarcoma cells, tumors were resected from mice and digested in 0.25% trypsin-EDTA
(Thermo fisher scientific; Waltham, MA, USA) for 1 h at 37 ◦C and cultured in the conditions described
above. For ex vivo sensitivity assays, cells were isolated from canine osteosarcomas harvested from
dogs that were undergoing routine amputation of the affected limb as part of routine clinical care
and not for the purposes of this study. Following amputation, 8-gauge core biopsies were taken from
primary tumors, ground with a mortar and pestle in 1 mg/mL collagenase/dispase (Sigma-Aldrich;
Castle Hill, NSW, Australia) and incubated with shaking at 800 rpm for 1 to 5 h at 37 ◦C. Cells were
passed through a 0.4 µm cell strainer into α-MEM media (Lonza; Mount Waverley, VIC, Australia)
supplemented with 10% FBS and 2 mM L-Glutamine, 100 U Penicillin and 0.1 mg/mL Streptomycin
(Sigma-Aldrich; NSW, Australia).
4.2. Drugs
The drugs used in this study were bortezomib, ixazomib, carfilzomib (Selleck Chemicals; Houston,
TX, USA), doxorubicin and cisplatin (Sigma; NSW, Australia).
4.3. Animal Studies
Animal experiments were conducted in accordance with Australian Code of Practice for the Care
and Use of Animals for Scientific Purposes, as approved by the La Trobe Animal Ethics Committee
(approval AEC 17–76).
Five to six-week-old BALB/c-Foxn1nu/Arc (“nude”) mice were purchased from the ARC (Australia)
and housed at La Trobe Animal Research facility in individual ventilated cages, with 12-h light/dark
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cycling and unrestricted access to food and water. Mice were monitored and weighed each day.
Euthanasia was performed by CO2 asphyxiation or cervical dislocation. KRIB-luc intramuscular
primary tumor models were generated and imaged as previously described [30]. Mice were ranked
based on the bioluminescent value of their tumors one week after implantation of cells and alternately
distributed. Mice bearing 143B-luc and KRIB-luc pulmonary metastases were generated and imaged as
previously described [41]. Mice were imaged twice weekly until a lung tumor was detected, alternately
allocated to treatment groups, and then treatment with drugs or saline commenced the following day.
Mice were imaged once per week post tumor detection until the endpoint of the experiment.
Metastases were imaged by bioluminescence ex vivo at the endpoint of experiments. Mice were
intraperitoneally injected with 150 mg/kg D-luciferin (Pure Science; Porirua, New Zealand) and
humanely euthanized ten minutes later. Organs were removed from mice, placed in a small petri
dish containing 15 mg/mL D-luciferin and imaged immediately. Circular regions of interest were
drawn around organs to measure bioluminescence intensity using living image software version
4.7.2 (Perkin Elmer; Waltham, MA, USA) corresponding to the level of luciferase expressing tumor
cells present.
Control mice were injected with saline intraperitoneally using a 27-gauge needle twice weekly
for four weeks. Bortezomib was dissolved in PBS to 0.1 mg/mL and administered intraperitoneally
with a 27-gauge needle twice per week for 4 weeks at 1 mg/kg. Ixazomib was dissolved in 10%
(2-Hydroxypropyl)-β-cyclodextrin to 1 mg/mL and administered by oral gavage twice per week for
4 weeks.
4.4. Cell Viability Assays
Five hundred canine or 2000 human osteosarcoma cells respectively were seeded in white 96-well
plates containing drugs or media to a final volume of 100 µL and incubated for a specified time.
Luminescence, reflecting ATP levels in viable cells was measured using the CellTiter-Glo 2.0 kit
(Promega; Fitchburg, WI, USA) as described [76].
4.5. Immunofluorescence
Tissue was incubated in formalin for at least 48 h before being embedded in paraffin wax.
Four-micron sections were cut from paraffin blocks and mounted on Menzel-Glaser Superfrost Plus®
microscope slides (Thermo fisher scientific; MA, USA). Slides were dried overnight at 37 ◦C before
being incubated at 65 ◦C for 10 min. Slides were dewaxed, stained and cleared by two 4-min incubations
in xylene (Amber scientific; Midvale, WA, Australia), two 2 min incubations in 100% ethanol, tap water
for 5 min. Antigen retrieval was performed in a pressure cooker in 10 mM sodium citrate pH 6.0
at 110 ◦C for 10 min. Tissue sections were permeabilized with 1% Triton X-100 in PBS for 10 min at
room temperature and blocked for one hour with PBS containing 1% BSA and 0.1% Tween20 for one
hour at room temperature in a humidified chamber. Block solution was aspirated from the sections
and stained with anti CD31-eFluor450 and isotype control rat IgG2 aκ-eFluor450 (1:200) (Thermo
Fisher Scientific; Waltham, MA, USA) or anti CD44-FITC and isotype control rat IgG2a-FITC (1:300)
(SouthernBiotech; Birmingham, AL, USA). All antibodies were diluted in block solution and incubated
overnight at 4 ◦C in a humidified chamber. Sections were washed 3x in PBS containing 0.1% Tween20
for five minutes with shaking. Coverslips were mounted on slides with acqueous mounting medium
(Abcam; Cambridge, UK). Slides were imaged on a Zeis 780 confocal microscope and images analyzed
using Zen 3.1 blue edition.
4.6. Pharmacodynamics
Tissue from treated and untreated mice was harvested and frozen immediately. Frozen tissue was
mechanically homogenized on ice in hypotonic lysis buffer (50 mM HEPES, pH 8.0) [56]. Samples were
sonicated using a microson ultrasonic cell disruptor (Misonix; Farmingdale, NY, USA), centrifuged at
13,000× g for 5 min at 4 ◦C and mixed 1:1 with stabilization solution (40 mM HEPES, 1 mM EDTA,
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20% glycerol, pH 8.0). Protein was quantitated using a micro BCA kit (Thermo Fisher Scientific).
LLVYase activity, which reflects chymotrypsin-like proteasome activity [56], was measured in reactions
containing activity buffer (0.5 mM ATP, 1 mM DTT, 0.5 mg/mL BSA) and 100 µM Suc-LLVY-AMC
(Enzo Life Sciences; Farmingdale, NY, USA). Fluorescence was measured using a Spectramax M5
(Molecular Devices; San Jose, CA, USA) and slope of the curve interpolated using GraphPad Prism 8.0
(GraphPad; San Diego, CA, USA).
4.7. Statistics
All statistical analyses were performed using GraphPad Prism 8.0 (GraphPad) software.
5. Conclusions
Ixazomib and bortezomib both inhibited the growth of KRIB-luc pulmonary osteosarcoma
metastases but only ixazomib enhanced the survival of mice and inhibited the growth of aggressive
pulmonary and abdominal 143B-luc osteosarcoma metastases. Neither proteasome inhibitor was
effective against poorly vascularized primary tumors, implying that tumor vascularity is a determinant
of efficacy of proteasome inhibitors as a class, against solid tumors. Our results warrant the further
investigation of ixazomib as a potential new therapy for metastatic osteosarcoma, especially if future
experiments demonstrate cooperation with currently used treatments in vivo.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/5/1207/s1,
Figure S1: Ixazomib toxicity.
Author Contributions: Conceptualization, M.A.H. and C.J.H.; data curation, M.A.H.; formal analysis, M.A.H.
and C.J.H.; funding acquisition, C.J.H.; methodology, M.A.H., M.A.M., T.M.S., C.C., S.R.G., S.D.R. and C.M.C.;
project administration, S.D.R., C.M.C. and C.J.H.; resources, C.J.H.; supervision, C.J.H.; validation, M.A.H. and
C.J.H.; writing—original draft, M.A.H. and C.J.H.; writing—review and editing, M.A.H., M.A.M., T.M.S., C.C.,
S.R.G., S.D.R., C.M.C. and C.J.H. All authors have read and agreed to the published version of the manuscript.
Funding: This research was funded by grants from The Kids’ Cancer Project and the Canine Research Foundation.
Acknowledgments: We thank Peter Lock and the La Trobe Institute for Molecular Science BioImaging Facility for
assistance with microscopy, Matilda Mikic for assistance with tissue processing, Dain Maxwell and Jacqueline
Orian for providing histology training and La Trobe Animal Research and Training Facility for assistance with
animal experiments.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Mirabello, L.; Troisi, R.J.; Savage, S.A. International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int. J. Cancer 2009, 125, 229–234. [CrossRef]
2. Gianferante, D.M.; Mirabello, L.; Savage, S.A. Germline and somatic genetics of osteosarcoma - connecting
aetiology, biology and therapy. Nat. Rev. Endocrinol. 2017, 13, 480–491. [CrossRef]
3. McGuire, J.; Utset-Ward, T.; Reed, D.; Lynch, C.C. Re-calculating! Navigating through the osteosarcoma
treatment roadblock. Pharmacol. Res. 2017, 117, 54–64. [CrossRef]
4. Allison, D.C.; Carney, S.C.; Ahlmann, E.R.; Hendifar, A.; Chawla, S.; Fedenko, A.; Angeles, C.; Menendez, L.R.
A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 2012, 704872. [CrossRef]
5. Meazza, C.; Scanagatta, P. Metastatic osteosarcoma: A challenging multidisciplinary treatment. Expert Rev.
Anticancer Ther. 2016, 16, 543–556. [CrossRef]
6. Richardson, P.G.; Sonneveld, P.; Schuster, M.W.; Irwin, D.; Stadtmauer, E.A.; Facon, T.; Harousseau, J.-L.;
Ben-Yehuda, D.; Lonial, S.; Goldschmidt, H. Bortezomib or high-dose dexamethasone for relapsed multiple
myeloma. N. Engl. J. Med. 2005, 352, 2487–2498. [CrossRef] [PubMed]
7. Raedler, L. Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple
Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma. Am. Health Drug Benefits
2015, 8, 135–140. [PubMed]
8. Manasanch, E.E.; Orlowski, R.Z. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 2017, 14,
417–433. [CrossRef]
Cancers 2020, 12, 1207 15 of 18
9. Patatsos, K.; Shekhar, T.M.; Hawkins, C.J. Pre-clinical evaluation of proteasome inhibitors for canine and
human osteosarcoma. Vet. Comp. Oncol. 2018, 16, 544–553. [CrossRef] [PubMed]
10. Shapovalov, Y.; Benavidez, D.; Zuch, D.; Eliseev, R.A. Proteasome inhibition with bortezomib suppresses
growth and induces apoptosis in osteosarcoma. Int. J. Cancer 2010, 127, 67–76. [CrossRef] [PubMed]
11. Lou, Z.; Ren, T.; Peng, X.; Sun, Y.; Jiao, G.; Lu, Q.; Zhang, S.; Lu, X.; Guo, W. Bortezomib induces apoptosis
and autophagy in osteosarcoma cells through mitogen-activated protein kinase pathway in vitro. J. Int.
Med. Res. 2013, 41, 1505–1519. [CrossRef] [PubMed]
12. Blaney, S.M.; Bernstein, M.; Neville, K.; Ginsberg, J.; Kitchen, B.; Horton, T.; Berg, S.L.; Krailo, M.;
Adamson, P.C. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory
solid tumors: A Children’s Oncology Group study (ADVL0015). J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
2004, 22, 4804–4809. [CrossRef] [PubMed]
13. Maki, R.G.; Kraft, A.S.; Scheu, K.; Yamada, J.; Wadler, S.; Antonescu, C.R.; Wright, J.J.; Schwartz, G.K. A
multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005, 103, 1431–1438.
[CrossRef] [PubMed]
14. Marten, A.; Zeiss, N.; Serba, S.; Mehrle, S.; von Lilienfeld-Toal, M.; Schmidt, J. Bortezomib is ineffective in an
orthotopic mouse model of pancreatic adenocarcinoma. Mol. Cancer Ther. 2008, 7, 3624–3631. [CrossRef]
[PubMed]
15. Kupperman, E.; Lee, E.C.; Cao, Y.; Bannerman, B.; Fitzgerald, M.; Berger, A.; Yu, J.; Yang, Y.; Hales, P.;
Bruzzese, F.; et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Cancer Res. 2010, 70, 1970–1980. [CrossRef] [PubMed]
16. Huang, Z.; Wu, Y.; Zhou, X.; Xu, J.; Zhu, W.; Shu, Y.; Liu, P. Efficacy of therapy with bortezomib in solid
tumors: A review based on 32 clinical trials. Future Oncol. 2014, 10, 1795–1807. [CrossRef]
17. Roeten, M.S.F.; Cloos, J.; Jansen, G. Positioning of proteasome inhibitors in therapy of solid malignancies.
Cancer Chemother. Pharm. 2018, 81, 227–243. [CrossRef]
18. Flynt, E.; Bisht, K.; Sridharan, V.; Ortiz, M.; Towfic, F.; Thakurta, A. Prognosis, Biology, and Targeting of TP53
Dysregulation in Multiple Myeloma. Cells 2020, 9. [CrossRef]
19. Li, C.; Hu, J.; Li, W.; Song, G.; Shen, J. Combined bortezomib-based chemotherapy and p53 gene therapy using
hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Biomater. Sci.
2016, 5, 77–88. [CrossRef]
20. Ling, X.; Calinski, D.; Chanan-Khan, A.A.; Zhou, M.; Li, F. Cancer cell sensitivity to bortezomib is associated
with survivin expression and p53 status but not cancer cell types. J. Exp. Clin. Cancer Res. 2010, 29, 8.
[CrossRef]
21. Buscail, L.; Bournet, B.; Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of
pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2020, 17, 153–168. [CrossRef] [PubMed]
22. Chiu, H.W.; Lin, S.W.; Lin, L.C.; Hsu, Y.H.; Lin, Y.F.; Ho, S.Y.; Wu, Y.H.; Wang, Y.J. Synergistic antitumor effects
of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy
and the downregulation of TRAF6. Cancer Lett. 2015, 365, 229–239. [CrossRef] [PubMed]
23. Michaelis, M.; Fichtner, I.; Behrens, D.; Haider, W.; Rothweiler, F.; Mack, A.; Cinatl, J.; Doerr, H.W.; Cinatl, J.
Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo.
Int. J. Oncol. 2006, 28, 439–446. [CrossRef] [PubMed]
24. Bersani, F.; Taulli, R.; Accornero, P.; Morotti, A.; Miretti, S.; Crepaldi, T.; Ponzetto, C. Bortezomib-mediated
proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. Eur. J. Cancer 2008, 44,
876–884. [CrossRef]
25. Brignole, C.; Marimpietri, D.; Pastorino, F.; Nico, B.; Di Paolo, D.; Cioni, M.; Piccardi, F.; Cilli, M.; Pezzolo, A.;
Corrias, M.V.; et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.
J. Natl. Cancer Inst. 2006, 98, 1142–1157. [CrossRef]
26. Bullova, P.; Cougnoux, A.; Marzouca, G.; Kopacek, J.; Pacak, K. Bortezomib Alone and in Combination With
Salinosporamid A Induces Apoptosis and Promotes Pheochromocytoma Cell Death In Vitro and in Female
Nude Mice. Endocrinology 2017, 158, 3097–3108. [CrossRef]
27. Williamson, M.J.; Silva, M.D.; Terkelsen, J.; Robertson, R.; Yu, L.; Xia, C.; Hatsis, P.; Bannerman, B.; Babcock, T.;
Cao, Y.; et al. The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and
efficacy of bortezomib in mouse xenograft models. Mol. Cancer Ther. 2009, 8, 3234–3243. [CrossRef]
Cancers 2020, 12, 1207 16 of 18
28. Zuccari, G.; Milelli, A.; Pastorino, F.; Loi, M.; Petretto, A.; Parise, A.; Marchetti, C.; Minarini, A.; Cilli, M.;
Emionite, L.; et al. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases
therapeutic activity in human neuroblastoma. J. Control Release 2015, 211, 44–52. [CrossRef]
29. Richardson, P.G.; Zweegman, S.; O’Donnell, E.K.; Laubach, J.P.; Raje, N.; Voorhees, P.; Ferrari, R.H.; Skacel, T.;
Kumar, S.K.; Lonial, S. Ixazomib for the treatment of multiple myeloma. Expert Opin. Pharm. 2018, 19,
1949–1968. [CrossRef]
30. Okazuka, K.; Ishida, T. Proteasome inhibitors for multiple myeloma. Jpn. J. Clin. Oncol. 2018, 48, 785–793.
[CrossRef]
31. Liu, R.; Fu, C.; Sun, J.; Wang, X.; Geng, S.; Wang, X.; Zou, J.; Bi, Z.; Yang, C. A New Perspective for
Osteosarcoma Therapy: Proteasome Inhibition by MLN9708/2238 Successfully Induces Apoptosis and Cell
Cycle Arrest and Attenuates the Invasion Ability of Osteosarcoma Cells in Vitro. Cell Physiol. Biochem. 2017,
41, 451–465. [CrossRef]
32. Mirabello, L.; Troisi, R.J.; Savage, S.A. Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program. Cancer 2009, 115, 1531–1543. [CrossRef]
[PubMed]
33. Whelan, J.S.; Bielack, S.S.; Marina, N.; Smeland, S.; Jovic, G.; Hook, J.M.; Krailo, M.; Anninga, J.;
Butterfass-Bahloul, T.; Bohling, T.; et al. EURAMOS-1, an international randomised study for osteosarcoma:
Results from pre-randomisation treatment. Ann. Oncol. 2015, 26, 407–414. [CrossRef] [PubMed]
34. Marina, N.M.; Smeland, S.; Bielack, S.S.; Bernstein, M.; Jovic, G.; Krailo, M.D.; Hook, J.M.; Arndt, C.; van
den Berg, H.; Brennan, B.; et al. Comparison of MAPIE versus MAP in patients with a poor response to
preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): An open-label,
international, randomised controlled trial. Lancet Oncol. 2016, 17, 1396–1408. [CrossRef]
35. Meyers, P.A.; Schwartz, C.L.; Krailo, M.; Kleinerman, E.S.; Betcher, D.; Bernstein, M.L.; Conrad, E.;
Ferguson, W.; Gebhardt, M.; Goorin, A.M.; et al. Osteosarcoma: A randomized, prospective trial of the
addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
J. Clin. Oncol. 2005, 23, 2004–2011. [CrossRef] [PubMed]
36. Rowell, J.L.; McCarthy, D.O.; Alvarez, C.E. Dog models of naturally occurring cancer. Trends Mol. Med. 2011,
17, 380–388. [CrossRef]
37. Mueller, F.; Fuchs, B.; Kaser-Hotz, B. Comparative biology of human and canine osteosarcoma. Anticancer Res.
2007, 27, 155–164.
38. Simpson, S.; Dunning, M.D.; de Brot, S.; Grau-Roma, L.; Mongan, N.P.; Rutland, C.S. Comparative
review of human and canine osteosarcoma: Morphology, epidemiology, prognosis, treatment and genetics.
Acta Vet. Scand. 2017, 59, 71. [CrossRef]
39. Shekhar, T.M.; Burvenich, I.J.G.; Harris, M.A.; Rigopoulos, A.; Zanker, D.; Spurling, A.; Parker, B.S.;
Walkley, C.R.; Scott, A.M.; Hawkins, C.J. Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth
and metastasis in mice. BMC Cancer 2019, 19, 924. [CrossRef]
40. Mori, Y.; Shirai, T.; Terauchi, R.; Tsuchida, S.; Mizoshiri, N.; Hayashi, D.; Arai, Y.; Kishida, T.; Mazda, O.;
Kubo, T. Antitumor effects of pristimerin on human osteosarcoma cells in vitro and in vivo. Oncotargets Ther.
2017, 10, 5703–5710. [CrossRef]
41. Harris, M.A.; Shekhar, T.M.; Coupland, L.A.; Miles, M.A.; Hawkins, C.J. Transient NK cell depletion facilitates
pulmonary osteosarcoma metastases after intravenous inoculation in athymic mice. JAYAO 2020, in press.
42. Moreau, P.; Karamanesht, I.I.; Domnikova, N.; Kyselyova, M.Y.; Vilchevska, K.V.; Doronin, V.A.; Schmidt, A.;
Hulin, C.; Leleu, X.; Esseltine, D.L.; et al. Pharmacokinetic, pharmacodynamic and covariate analysis of
subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Clin. Pharmacokinet. 2012, 51, 823–829. [CrossRef] [PubMed]
43. Richardson, P.G.; Baz, R.; Wang, M.; Jakubowiak, A.J.; Laubach, J.P.; Harvey, R.D.; Talpaz, M.; Berg, D.; Liu, G.;
Yu, J.; et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory
multiple myeloma patients. Blood 2014, 124, 1038–1046. [CrossRef] [PubMed]
44. Quach, H.; White, D.; Spencer, A.; Ho, P.J.; Bhutani, D.; White, M.; Inamdar, S.; Morris, C.; Ou, Y.; Gyger, M.
Pharmacokinetics and safety of carfilzomib in patients with relapsed multiple myeloma and end-stage renal
disease (ESRD): An open-label, single-arm, phase I study. Cancer Chemother. Pharmacol. 2017, 79, 1067–1076.
[CrossRef] [PubMed]
Cancers 2020, 12, 1207 17 of 18
45. Rushing, D.A.; Piscitelli, S.C.; Rodvold, K.A.; Tewksbury, D.A. The disposition of doxorubicin on repeated
dosing. J. Clin. Pharm. 1993, 33, 698–702. [CrossRef] [PubMed]
46. van Hennik, M.B.; van der Vijgh, W.J.; Klein, I.; Elferink, F.; Vermorken, J.B.; Winograd, B.; Pinedo, H.M.
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res. 1987, 47,
6297–6301.
47. Kirpensteijn, J.; Kik, M.; Teske, E.; Rutteman, G.R. TP53 gene mutations in canine osteosarcoma. Vet. Surg.
2008, 37, 454–460. [CrossRef]
48. Fenger, J.M.; London, C.A.; Kisseberth, W.C. Canine osteosarcoma: A naturally occurring disease to inform
pediatric oncology. Inst. Lab. Anim. Res. J. 2014, 55, 69–85. [CrossRef]
49. Zhang, Y.; Yang, J.; Zhao, N.; Wang, C.; Kamar, S.; Zhou, Y.; He, Z.; Yang, J.; Sun, B.; Shi, X.; et al. Progress in
the chemotherapeutic treatment of osteosarcoma. Oncol. Lett. 2018, 16, 6228–6237. [CrossRef] [PubMed]
50. Selmic, L.E.; Burton, J.H.; Thamm, D.H.; Withrow, S.J.; Lana, S.E. Comparison of carboplatin and
doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular
osteosarcoma. J. Vet. Intern. Med. 2014, 28, 554–563. [CrossRef]
51. Gaver, R.C.; George, A.M.; Duncan, G.F.; Morris, A.D.; Deeb, G.; Faulkner, H.C.; Farmen, R.H. The disposition
of carboplatin in the beagle dog. Cancer Chemother. Pharmacol. 1988, 21, 197–202. [CrossRef] [PubMed]
52. Chang, Y.-C.; Lo, W.-J.; Huang, Y.-T.; Lin, C.-L.; Feng, C.-C.; Lin, H.-T.; Cheng, H.-C.; Yeh, S.-P. Deferasirox
has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin. Leuk. Lymphoma
2017, 58, 1–12. [CrossRef] [PubMed]
53. Uddin, S.; Ahmed, M.; Bavi, P.; El-Sayed, R.; Al-Sanea, N.; AbdulJabbar, A.; Ashari, L.H.; Alhomoud, S.;
Al-Dayel, F.; Hussain, A.R.; et al. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase
protein 2 degradation in colorectal cancer. Cancer Res. 2008, 68, 3379–3388. [CrossRef] [PubMed]
54. Park, J.; Park, E.; Jung, C.-K.; Kang, S.-W.; Kim, B.G.; Jung, Y.; Kim, T.H.; Lim, J.-Y.; Lee, S.-E.; Min, C.-K.; et al.
Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer 2016, 16, 247.
[CrossRef] [PubMed]
55. Augello, G.; Modica, M.; Azzolina, A.; Puleio, R.; Cassata, G.; Emma, M.R.; Di Sano, C.; Cusimano, A.;
Montalto, G.; Cervello, M. Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238
(ixazomib) in hepatocellular carcinoma cells. Cell Death Dis. 2018, 9, 28. [CrossRef]
56. Kisselev, A.F.; Goldberg, A.L. Monitoring Activity and Inhibition of 26S Proteasomes with Fluorogenic
Peptide Substrates. Methods Enzymol. 2005, 398, 364–378. [CrossRef]
57. Goyal, S.; Julka, P.K. Recurrent osteosarcoma with calcified liver metastases: Uncommon development of a
common disease. J. Cancer Res. Ther. 2017, 13, 139–141. [CrossRef] [PubMed]
58. Jeffree, G.M.; Price, C.H.; Sissons, H.A. The metastatic patterns of osteosarcoma. Br. J. Cancer 1975, 32, 87–107.
[CrossRef] [PubMed]
59. Xian, M.; Cao, H.; Cao, J.; Shao, X.; Zhu, D.; Zhang, N.; Huang, P.; Li, W.; Yang, B.; Ying, M.; et al. Bortezomib
sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of
p-eIF2α/ATF4/CHOP axis. Int. J. Cancer 2017, 141, 1029–1041. [CrossRef]
60. Zhao, Y.; Foster, N.R.; Meyers, J.P.; Thomas, S.P.; Northfelt, D.W.; Rowland, K.M., Jr.; Mattar, B.I.; Johnson, D.B.;
Molina, J.R.; Mandrekar, S.J.; et al. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin,
and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment
Group (NCCTG)-N0321. J. Thorac. Oncol. 2015, 10, 172–180. [CrossRef]
61. Aghajanian, C.; Dizon, D.S.; Sabbatini, P.; Raizer, J.J.; Dupont, J.; Spriggs, D.R. Phase I trial of bortezomib and
carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. 2005, 23, 5943–5949. [CrossRef]
[PubMed]
62. Taromi, S.; Lewens, F.; Arsenic, R.; Sedding, D.; Sänger, J.; Kunze, A.; Möbs, M.; Benecke, J.; Freitag, H.;
Christen, F.J.O. Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell
lung cancer. Oncotarget 2017, 8, 97061. [CrossRef] [PubMed]
63. Davies, A.M.; Chansky, K.; Lara, P.N., Jr.; Gumerlock, P.H.; Crowley, J.; Albain, K.S.; Vogel, S.J.; Gandara, D.R.;
Southwest Oncology, G. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced
non-small cell lung cancer: A phase II Southwest Oncology Group Study (S0339). J. Thorac. Oncol. Off. Publ.
Int. Assoc. Study Lung Cancer 2009, 4, 87–92. [CrossRef] [PubMed]
Cancers 2020, 12, 1207 18 of 18
64. Piperdi, B.; Walsh, W.V.; Bradley, K.; Zhou, Z.; Bathini, V.; Hanrahan-Boshes, M.; Hutchinson, L.; Perez-Soler, R.
Phase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in
patients with advanced non-small-cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer
2012, 7, 1032–1040. [CrossRef] [PubMed]
65. Grantab, R.H.; Tannock, I.F. Penetration of anticancer drugs through tumour tissue as a function of cellular
packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer 2012, 12, 214.
[CrossRef] [PubMed]
66. Wang, H.; Yu, Y.; Jiang, Z.; Cao, W.M.; Wang, Z.; Dou, J.; Zhao, Y.; Cui, Y.; Zhang, H. Next-generation
proteasome inhibitor MLN9708 sensitizes breast cancer cells to doxorubicin-induced apoptosis. Sci. Rep.
2016, 6, 26456. [CrossRef]
67. Al-Eisawi, Z.; Beale, P.; Chan, C.; Jun, Q.Y.; Huq, F. Carboplatin and oxaliplatin in sequenced combination
with bortezomib in ovarian tumour models. J. Ovarian Res. 2013, 6, 78. [CrossRef] [PubMed]
68. Daniel, K.G.; Kuhn, D.J.; Kazi, A.; Dou, Q.P. Anti-angiogenic and anti-tumor properties of proteasome
inhibitors. Curr. Cancer Drug Targets 2005, 5, 529–541. [CrossRef] [PubMed]
69. Kreuter, M.; Bieker, R.; Bielack, S.S.; Auras, T.; Buerger, H.; Gosheger, G.; Jurgens, H.; Berdel, W.E.;
Mesters, R.M. Prognostic Relevance of Increased Angiogenesis in Osteosarcoma. Clin. Cancer Res. 2004, 10,
8531–8537. [CrossRef]
70. Oda, Y.; Yamamoto, H.; Tamiya, S.; Matsuda, S.; Tanaka, K.; Yokoyama, R.; Iwamoto, Y.; Tsuneyoshi, M.
CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis
within a group of patients, all of whom developed lung metastasis. Mod. Pathol. 2006, 19, 738–745. [CrossRef]
71. Rastogi, S.; Kumar, R.; Sankineani, S.R.; Marimuthu, K.; Rijal, L.; Prakash, S.; Jalan, D.; Khan, S.A.;
Sharma, M.C. Role of vascular endothelial growth factor as a tumour marker in osteosarcoma: A prospective
study. Int. Orthop. 2012, 36, 2315–2321. [CrossRef] [PubMed]
72. Shen, Y.; Li, S.; Wang, X.; Wang, M.; Tian, Q.; Yang, J.; Wang, J.; Wang, B.; Liu, P.; Yang, J. Tumor vasculature
remolding by thalidomide increases delivery and efficacy of cisplatin. J. Exp. Clin. Cancer Res. 2019, 38, 427.
[CrossRef] [PubMed]
73. Budzynski, W.; Radzikowski, C. Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol.
Immunotoxicol. 1994, 16, 319–346. [CrossRef] [PubMed]
74. Shanker, A.; Pellom, S.T., Jr.; Dudimah, D.F.; Thounaojam, M.C.; de Kluyver, R.L.; Brooks, A.D.; Yagita, H.;
McVicar, D.W.; Murphy, W.J.; Longo, D.L.; et al. Bortezomib Improves Adoptive T-cell Therapy by Sensitizing
Cancer Cells to FasL Cytotoxicity. Cancer Res. 2015, 75, 5260–5272. [CrossRef]
75. Pellom, S.T., Jr.; Dudimah, D.F.; Thounaojam, M.C.; Uzhachenko, R.V.; Singhal, A.; Richmond, A.; Shanker, A.
Bortezomib augments lymphocyte stimulatory cytokine signaling in the tumor microenvironment to sustain
CD8+T cell antitumor function. Oncotarget 2017, 8, 8604–8621. [CrossRef] [PubMed]
76. Shekhar, T.M.; Miles, M.A.; Gupte, A.; Taylor, S.; Tascone, B.; Walkley, C.R.; Hawkins, C.J. IAP antagonists
sensitize murine osteosarcoma cells to killing by TNFα. Oncotarget 2016, 7, 33866–33886. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
